Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia.
Maximilian StahlGerard GiblinYiwen LiuEric S WinerJacqueline S GarciaEvan ChenMartha WadleighKelly LingR Coleman LindsleyShai ShimonyKevin CopsonAnne CharlesDaniel J DeAngeloRichard M StoneAnju NohriaMarlise R LuskinPublished in: Leukemia research (2023)
In a group of AML patients with normal LVEF prior to anthracycline-containing induction chemotherapy, ARLVD was infrequent and did not commonly preclude post-remission allo-SCT consolidation. Genetic predictors of ARLVD require further investigation in a larger patient cohort.
Keyphrases
- left ventricular
- acute myeloid leukemia
- heart failure
- case report
- oxidative stress
- acute myocardial infarction
- genome wide
- hypertrophic cardiomyopathy
- mitral valve
- locally advanced
- disease activity
- cardiac resynchronization therapy
- gene expression
- radiation therapy
- rheumatoid arthritis
- aortic valve
- atrial fibrillation
- ejection fraction